35 completed, 12 terminated, 3 recruiting, 1 withdrawn. 28 Phase 2, 25 Phase 1, 6 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 28 | Completed 19, Terminated 8, Withdrawn 1 |
| Phase 1 | 25 | Completed 21, Terminated 4 |
| Not applicable | 6 | Terminated 3, Completed 2, Recruiting 1 |
Follow Recurrent Renal Cell Cancer: new trials by email Literature Review of Recurrent Renal Cell Cancer trials Research Report on Recurrent Renal Cell Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CAIX PET/ CT Guided Radiation Therapy in CcRCC. PETCT-guided radiation therapy - Radiation Therapy, Metastatic Renal Cancer | Not applicable | Recruiting | Peking University First Hospital | 70 | 2025-11-01 | 2026-04-20 |
| SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer Radiation therapy, Targeted and immunotherapy - Radiation Therapy, Metastatic Renal Cancer | Recruiting | Peking University First Hospital | 300 | 2024-02-02 | 2026-01-28 | |
| Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma 89Zr-Girentuximab - Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma | Phase 1 | Completed | Telix Pharmaceuticals (Innovations) Pty Limited | 10 | 2023-06-26 | 2023-12-11 |
| Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC) Clear Cell Renal Cell Carcinoma, Prognostic Cancer Model | Recruiting | Mingzhao Xiao | 800 | 2022-09-01 | 2025-05-31 | |
| Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene A166 - HER2-positive Breast Cancer, HER2 Gene Mutation | Phase 1 / Phase 2 | Completed | Klus Pharma Inc. | 49 | 2018-07-16 | 2023-08-03 |
| APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery siRNA-transfected peripheral blood mononuclear cells APN401, laboratory biomarker analysis - Recurrent Melanoma, Recurrent Pancreatic Cancer | Phase 1 | Completed | Wake Forest University Health Sciences | 17 | 2014-12-01 | 2018-07-03 |
| Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Everolimus - Estrogen Receptor-positive Breast Cancer, Gastrinoma | Phase 2 | Terminated | Emory University | 2 | 2014-11-01 | 2017-02-03 |
| Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer stereotactic body radiation therapy, cyclophosphamide, therapeutic autologous lymphocytes - Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer | Phase 1 | Terminated | Stanford University | 2 | 2014-05-01 | 2017-03-15 |
| Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers educational intervention, telephone-based intervention, quality-of-life assessment - Healthy Subject, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter | Not applicable | Completed | City of Hope Medical Center | 200 | 2013-10-29 | 2026-10-01 |
| Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery stereotactic body radiation therapy, therapeutic conventional surgery, laboratory biomarker analysis - Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer | Not applicable | Completed | Roswell Park Cancer Institute | 15 | 2013-07-11 | 2022-07-22 |
| 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2 - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 / Phase 2 | Completed | Sanjiv Sam Gambhir | 25 | 2013-03-04 | 2019-10-03 |
| Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer AdGMCAIX-transduced autologous dendritic cells, therapeutic autologous dendritic cells, laboratory biomarker analysis - Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer | Phase 1 | Completed | Jonsson Comprehensive Cancer Center | 12 | 2013-01-14 | 2021-08-04 |
| Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer transcranial magnetic stimulation, electromyography, survey administration - Fatigue, Recurrent Renal Cell Cancer | Not applicable | Terminated | Case Comprehensive Cancer Center | 13 | 2012-09-01 | 2018-12-06 |
| Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer pazopanib hydrochloride, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging - Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer | Not applicable | Terminated | University of Chicago | 20 | 2012-06-01 | 2017-06-08 |
| Clamped or Unclamped Surgery in Treating Patients With Kidney Cancer robot-assisted laparoscopic surgery - Recurrent Renal Cell Cancer | Not applicable | Terminated | University of Southern California | 28 | 2011-12-01 | 2015-03-27 |
| Fluorescence Imaging in Finding Tumors in Patients With Kidney Tumors fluorescence imaging, laparoscopic surgery, indocyanine green - Recurrent Renal Cell Cancer, Stage I Renal Cell Cancer | Phase 1 | Completed | City of Hope Medical Center | 28 | 2011-10-20 | 2017-10-13 |
| Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer pazopanib hydrochloride, laboratory biomarker analysis, immunologic technique - Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer | Phase 2 | Completed | City of Hope Medical Center | 28 | 2010-12-08 | 2022-06-08 |
| Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies sunitinib malate, bevacizumab, pharmacological study - Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 6 | 2010-10-01 | 2014-04-02 |
| Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors temsirolimus, gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis - Endometrial Papillary Serous Carcinoma, Recurrent Endometrial Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 18 | 2010-08-01 | 2014-05-30 |
| Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors temsirolimus, vinorelbine ditartrate - Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma | Phase 1 | Completed | University of Southern California | 19 | 2010-06-01 | 2016-06-13 |
Showing 20 of 51. Sign in to see all of them.
Carcinoma, Renal Cell (51) · Breast Neoplasms (7) · Colonic Neoplasms (6) · Melanoma (6) · Breast Neoplasms, Male (5) · Carcinoma, Ovarian Epithelial (5) · Pancreatic Neoplasms (5) · Rectal Neoplasms (5) · Carcinoma, Islet Cell (4) · Carcinoma, Non-Small-Cell Lung (4) · Prostatic Neoplasms (4) · Salivary Gland Neoplasms (4) · Stomach Neoplasms (4) · Uterine Cervical Neoplasms (4) · Burkitt Lymphoma (3)
Adenocarcinoma (51) · Carcinoma (51) · Female Urogenital Diseases (51) · Female Urogenital Diseases and Pregnancy Complications (51) · Kidney Diseases (51) · Male Urogenital Diseases (51) · Neoplasms by Histologic Type (51) · Neoplasms by Site (51) · Neoplasms, Glandular and Epithelial (51) · Urogenital Diseases (51) · Urogenital Neoplasms (51) · Urologic Diseases (51) · Kidney Neoplasms (49) · Neoplasms (49) · Urologic Neoplasms (48)
Bevacizumab (5) · Introns (4) · temsirolimus (4) · Cyclosporine (3) · Everolimus (3) · Mycophenolic Acid (3) · Peripheral Blood Stem Cell Transplantation (3) · Sirolimus (3) · Sorafenib (3) · Sunitinib (3) · Whole-Body Irradiation (3) · fludarabine phosphate (3) · Bryostatins (2) · Interferon Alfa-n3 (2) · Interferon alpha-2 (2)
National Cancer Institute (NCI) (27) · City of Hope Medical Center (3) · Fred Hutchinson Cancer Center (3) · Jonsson Comprehensive Cancer Center (2) · Peking University First Hospital (2) · Roswell Park Cancer Institute (2) · University of Southern California (2) · Case Comprehensive Cancer Center (1) · Emory University (1) · Klus Pharma Inc. (1) · Mayo Clinic (1) · Mingzhao Xiao (1) · Sanjiv Sam Gambhir (1) · Stanford University (1) · Telix Pharmaceuticals (Innovations) Pty Limited (1)
United States (46) · China (4) · Italy (2) · Canada (1) · Germany (1)
Walter Stadler (5) · Brenda Sandmaier (2) · Christopher Ryan (2) · Agustin Garcia (1) · Alexandra Drakaki, MD (1) · Amit Oza (1) · Arlene Siefker-Radtke (1) · Barbara J. Gitlitz, MD (1) · Betty Ferrell (1) · Brian Rini, MD (1) · Clayton Lau, MD (1) · Daniel George (1) · David Maloney (1) · David Nanus (1) · David Solit (1)
PMID 32499241, PMID 22259028, PMID 24474568, PMID 25965900, PMID 26062933, PMID 26611425, PMID 27634566, PMID 28630212, PMID 30850872, PMID 31654285, PMID 32925563, PMID 38896853, PMID 41444455
N01CM62201 (3), P30CA015704 (3), U10CA032102 (3), N01CM62209 (2), U01CA062491 (2), U01CA070095 (2), N01CM17003 (1), N01CM17101 (1), N01CM17102 (1), N01CM62202 (1), N01CM62204 (1), N01CM62205 (1), P01CA018029 (1), P01CA078902 (1), P30CA006973 (1)